836 Results
Sort By:
Published on November 6, 2019
Promega said today it will develop its microsatellite instability (MSI) technology as an on-label, solid tumor companion diagnostic (CDx) to Merck’s blockbuster cancer immunotherapy Keytruda (pembrolizumab), through a global collaboration whose value was not disclosed. Promega’s MSI testing is designed to functionally measure the genomic accumulation of insertion or deletion…
Published on November 5, 2019
Ares Genetics, a subsidiary of molecular microbiology diagnostics and syndromic testing company Curetis, has launched an early access program for its molecular antibiotic susceptibility test (AST), that leverages next-generation sequencing (NGS) and artificial intelligence (AI) technologies. According to the company, the new test has multiple applications ranging from identifying antibiotic…
Published on October 29, 2019
Inivata CEO Clive Morris Inivata said today it will partner with the European Organisation for Research and Treatment of Cancer (EORTC) to study the company’s InVisionFirst-Lung liquid biopsy test in a Phase II trial designed to screen and monitor anaplastic lymphoma kinase (ALK)-positive non-small cell lung…
Published on October 11, 2019
Color and Verily Life Sciences said they will partner to return actionable genetic information to all participants in the Project Baseline Health Study, Verily’s four-year initiative to collect comprehensive health information to better understand health and the transition to disease. Project Baseline Health Study participants will have access to Color’s…
Published on October 10, 2019
UTC Laboratories—also known as Renaissance RX (RenRX)—and its three principals have agreed to pay a combined $42.6 million to settle federal allegations that they paid kickbacks in exchange for laboratory referrals for pharmacogenetic testing, as well as for furnishing and billing for tests that were not medically necessary, all in…
Published on October 8, 2019
Many complicated diseases make up cancer. The American Society of Clinical Oncology’s Cancer.Net provides “individualized guides for more than 120 types of cancer and related hereditary syndromes.” Selecting the right cancer treatment for an individual patient gets even more complex when considering the various diagnostic tests, the wide range of…
Published on October 8, 2019
Two leaders in genomics and molecular analysis, Illumina and QIAGEN, have announced a 15-year partnership that the companies say is aimed at increasing the availability and use of NGS-based in-vitro diagnostics (IVDs) for precision medicine applications. Under the terms of the agreement, Qiagen has received non-exclusive right to develop and…
Published on October 7, 2019
They have the world record for fastest sequencing-based diagnosis in the world, at 19.5 hours, but Rady Children’s Institute for Genomic Medicine (RCIGM) isn’t stopping there. “We aim to use sequencing to diagnose 10,000 children with rare diseases by sometime in 2022,” said Stephen Kingsmore, M.D., president and CEO of…
Published on October 4, 2019
Two new reference data sources, Mastermind and DECIPHER, are being added to Congenica’s clinical decision support platform for genomic data interpretation. Genomenon’s Mastermind, which is used by hundreds of genetic labs worldwide, has indexed nearly 7 million full text articles and 500,000 supplemental data sets and covers over 4.9 million…
Published on September 30, 2019
Edward Abrahams, Ph.D., has been president of the Personalized Medicine Coalition (PMC) since its founding in late 2004. After serving as an anchor partner for the Annual Personalized Medicine Conference in collaboration with Harvard Medical School from 2005 to 2015, PMC took over the programming and management of the conference…
Published on September 28, 2019
In a surprising result, a new clinical genomic trial in neonates in the NICU setting found no major difference in the diagnostic rate between whole genome sequencing (WGS) and whole exome sequencing (WES). The randomized clinical study, A Randomized Controlled Trial of the Analytic and Diagnostic Performance of Singleton and…
Published on September 19, 2019
The British sequencing company famous for producing ultra-long reads, Oxford Nanopore Technologies announced today that have entered into a non-exclusive license agreement with Caribou Biosciences for CRISPR-Cas9 enrichment for nanopore sequencing. Caribou has granted Oxford Nanopore a worldwide, non-exclusive license under foundational CRISPR-Cas9 intellectual property controlled by Caribou for nanopore…
Published on September 17, 2019
LunaPBC, the public-benefit corporation which oversees the LunaDNA community-owned genomic and health data platform, said today that members will now be able to access their electronic health records (EHRs) in the platform via Medfusion’s Patient Data application program interfaces (APIs), through a collaboration whose value was not disclosed. The integration,…
Published on September 17, 2019
Personalized medicine company Interpace Diagnostics announced that it has entered into a partnership to jointly develop, promote, and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Beijing-based Genecast Biotechnology of the Peoples Republic of China (“PRC”). Genecast provides diagnostic products and services to pharmaceutical and…
Published on September 13, 2019
Genomic Diagnostics company Veracyte says new data demonstrates the clinical and analytical validity of its Afirma Xpression Atlas (XA) genomic test, which was developed to help guide surgery and treatment decisions for patients with likely or confirmed thyroid cancer. This data is reported online in the journal Frontiers in Endocrinology. Veracyte develops…